Clinical trial
Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients
NCT00244114 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00244114 |
|---|---|
| Title | Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients |
| Official title | In Vitro Evaluation Of Allergic Reactions In Hemophilia B Subjects Who Have Exhibited A Systemic Allergic Response After Exposure To BeneFIX (Nonacog Alfa; Recombinant Factor IX) |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Hemophilia B |
| Intervention type | Drug, Procedure |
| Interventions | blood draw, Blood draw |
| Enrollment | 20 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Oct 25, 2005 |
| Last update posted | Feb 18, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: